Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Neoadjuvant Therapy for Early or Locally Advanced HER2-negative Breast Cancer
NCT05525767Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Mar 2022
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Pathological Complete Response at 24 months. Started Mar 2022; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05525767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525767.